{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T05:41:50Z","timestamp":1793943710316,"version":"4.8.0"},"reference-count":48,"publisher":"American Society of Hematology","issue":"13","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2012,3,29]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Maintaining results of successful induction therapy is an important goal in multiple myeloma. Here, members of the International Myeloma Working Group review the relevant data. Thalidomide maintenance therapy after autologous stem cell transplantation improved the quality of response and increased progression-free survival (PFS) significantly in all 6 studies and overall survival (OS) in 3 of them. In elderly patients, 2 trials showed a significant prolongation of PFS, but no improvement in OS. A meta-analysis revealed a significant risk reduction for PFS\/event-free survival and death. The role of thalidomide maintenance after melphalan, prednisone, and thalidomide is not well established. Two trials with lenalidomide maintenance treatment after autologous stem cell transplantation and one study after conventional melphalan, prednisone, and lenalidomide induction therapy showed a significant risk reduction for PFS and an increase in OS in one of the transplant trials. Maintenance therapy with single-agent bortezomib or in combination with thalidomide or prednisone has been studied. One trial revealed a significantly increased OS with a bortezomib-based induction and bortezomib maintenance therapy compared with conventional induction and thalidomide maintenance treatment. Maintenance treatment can be associated with significant side effects, and none of the drugs evaluated is approved for maintenance therapy. Treatment decisions for individual patients must balance potential benefits and risks carefully, as a widely agreed-on standard is not established.<\/jats:p>","DOI":"10.1182\/blood-2011-11-374249","type":"journal-article","created":{"date-parts":[[2012,1,24]],"date-time":"2012-01-24T07:19:21Z","timestamp":1327389561000},"page":"3003-3015","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":157,"title":["IMWG consensus on maintenance therapy in multiple myeloma"],"prefix":"10.1182","volume":"119","author":[{"given":"Heinz","family":"Ludwig","sequence":"first","affiliation":[{"name":"Department of Medicine I, Center for Oncology and Hematology, Wilhelminenspital, Vienna, Austria;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian G. M.","family":"Durie","sequence":"additional","affiliation":[{"name":"Southwest Oncology Group, International Myeloma Foundation and Cedars Sinai Comprehensive Cancer Center, Los Angeles, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"McCarthy","sequence":"additional","affiliation":[{"name":"Roswell Park Cancer Institute, Buffalo, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Palumbo","sequence":"additional","affiliation":[{"name":"Myeloma Unit, Division of Hematology, University of Torino, Azienda Ospedaliera Universitaria S. Giovanni Battista, Torino, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9sus","family":"San Miguel","sequence":"additional","affiliation":[{"name":"University Hospital of Salamanca, Salamanca, Spain;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart","family":"Barlogie","sequence":"additional","affiliation":[{"name":"Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gareth","family":"Morgan","sequence":"additional","affiliation":[{"name":"Haemato-Oncology Unit, Royal Marsden Hospital, London, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pieter","family":"Sonneveld","sequence":"additional","affiliation":[{"name":"Department of Hematology, Erasmus MC, Rotterdam, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Spencer","sequence":"additional","affiliation":[{"name":"Clinical Haematology\/Bone Marrow Transplant Department, Alfred Hospital, Melbourne, Victoria, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth C.","family":"Andersen","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute, Medical Oncology, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Facon","sequence":"additional","affiliation":[{"name":"Department of Hematology, Hospital Claude Huriez, Lille, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith A.","family":"Stewart","sequence":"additional","affiliation":[{"name":"Division of Hematology-Oncology, Mayo Clinic, Scottsdale, AZ;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hermann","family":"Einsele","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine II, University Hospital, W\u00fcrzburg, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria-Victoria","family":"Mateos","sequence":"additional","affiliation":[{"name":"University Hospital of Salamanca, Salamanca, Spain;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Wijermans","sequence":"additional","affiliation":[{"name":"Haga Hospital, The Hague, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"Waage","sequence":"additional","affiliation":[{"name":"Department of Hematology, St Olavs Hospital, Norwegian University of Science and Technology, Trondheim, Norway;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meral","family":"Beksac","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Clinical Microbiology, Ankara University School of Medicine, Ibn-i Sina Hospital, Ankara, Turkey;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul G.","family":"Richardson","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute, Medical Oncology, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyrille","family":"Hulin","sequence":"additional","affiliation":[{"name":"Hematology Department, University Hospital, Nancy, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruben","family":"Niesvizky","sequence":"additional","affiliation":[{"name":"Weill Cornell Medical College, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henk","family":"Lokhorst","sequence":"additional","affiliation":[{"name":"University Medical Center, Utrecht, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ola","family":"Landgren","sequence":"additional","affiliation":[{"name":"Metabolism Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. Leif","family":"Bergsagel","sequence":"additional","affiliation":[{"name":"Division of Hematology-Oncology, Mayo Clinic, Scottsdale, AZ;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Orlowski","sequence":"additional","affiliation":[{"name":"Department of Lymphoma\/Myeloma, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, TX;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Hinke","sequence":"additional","affiliation":[{"name":"WISP Research Institute, Langenfeld, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Cavo","sequence":"additional","affiliation":[{"name":"Ser\u00e0gnoli Institute of Haematology, Bologna School of Medicine, S. Orsola's University Hospital, Bologna, Italy; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Attal","sequence":"additional","affiliation":[{"name":"Service d'H\u00e9matologie, Hospital Purpan, Toulouse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"s2","key":"2019111807390352900_B1","article-title":"Lenalidomide plus melphalan and prednisone followed by lenalidomide maintenance provides favorable efficacy and health related quality-of-life in newly diagnosed multiple myeloma patients over 65 years [abstract].","volume":"96","author":"Dimopoulos","year":"2011","journal-title":"Haematologica"},{"key":"2019111807390352900_B2","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1001\/archinte.1975.00330010149019","article-title":"Remission maintenance therapy for multiple myeloma.","volume":"135","author":"Alexanian","year":"1975","journal-title":"Arch Intern Med"},{"issue":"6","key":"2019111807390352900_B3","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1182\/blood.V51.6.1005.bloodjournal5161005","article-title":"Unmaintained remissions in multiple myeloma.","volume":"51","author":"Alexanian","year":"1978","journal-title":"Blood"},{"issue":"1","key":"2019111807390352900_B4","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/bjc.1988.17","article-title":"A randomized trial of maintenance versus no maintenance melphalan and prednisone in responding multiple myeloma patients.","volume":"57","author":"Belch","year":"1988","journal-title":"Br J Cancer"},{"issue":"4","key":"2019111807390352900_B5","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1046\/j.1365-2141.2001.02857.x","article-title":"Interferon as therapy for multiple myeloma: an individual patient data overview of 24 randomized trials and 4012 patients.","volume":"113","author":"Myeloma Trialists' Collaborative Group","year":"2001","journal-title":"Br J Haematol"},{"issue":"11","key":"2019111807390352900_B6","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1023\/A:1026548226770","article-title":"Interferon-alpha treatment in multiple myeloma: meta-analysis of 30 randomized trials among 3948 patients.","volume":"11","author":"Fritz","year":"2000","journal-title":"Ann Oncol"},{"issue":"9","key":"2019111807390352900_B7","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1182\/blood.V99.9.3163","article-title":"Maintenance therapy with alternate-day prednisone improves survival in multiple myeloma patients.","volume":"99","author":"Berenson","year":"2002","journal-title":"Blood"},{"issue":"2","key":"2019111807390352900_B8","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1111\/j.1365-2141.2006.06405.x","article-title":"A randomized comparison of melphalan with prednisone or dexamethasone as induction therapy and dexamethasone or observation as maintenance therapy in multiple myeloma: NCIC CTG MY7.","volume":"136","author":"Shustik","year":"2007","journal-title":"Br J Haematol"},{"issue":"3","key":"2019111807390352900_B9","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1002\/1096-8652(200011)65:3<204::AID-AJH5>3.0.CO;2-H","article-title":"Randomized trial of alpha-interferon or dexamethasone as maintenance treatment for multiple myeloma.","volume":"65","author":"Alexanian","year":"2000","journal-title":"Am J Hematol"},{"key":"2019111807390352900_B10","doi-asserted-by":"crossref","DOI":"10.1002\/0470854200","volume-title":"Meta-Analysis of Controlled Clinical Trials","author":"Whitehead","year":"2002"},{"issue":"24","key":"2019111807390352900_B11","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1002\/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8","article-title":"Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints.","volume":"30:17","author":"Parmar","year":"1998","journal-title":"Stat Med"},{"issue":"8144","key":"2019111807390352900_B12","first-page":"697","article-title":"Interferon therapy in myelomatosis.","volume":"2","author":"Mellstedt","year":"1979","journal-title":"Lancet"},{"issue":"6","key":"2019111807390352900_B13","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1038\/sj.bmt.1704633","article-title":"Single agent dexamethasone for pre-stem cell transplant induction therapy for multiple myeloma.","volume":"34","author":"Kumar","year":"2004","journal-title":"Bone Marrow Transplant"},{"issue":"28","key":"2019111807390352900_B14","doi-asserted-by":"crossref","first-page":"4452","DOI":"10.1200\/JCO.2007.12.3323","article-title":"Phase II PETHEMA Trial of alternating bortezomib and dexamethasone as induction regimen before autologous stem-cell transplantation in younger patients with multiple myeloma: efficacy and clinical implications of tumor response kinetics.","volume":"25","author":"Rosignol","year":"2007","journal-title":"J Clin Oncol"},{"issue":"10","key":"2019111807390352900_B15","doi-asserted-by":"crossref","first-page":"3289","DOI":"10.1182\/blood-2006-05-022962","article-title":"Maintenance therapy with thalidomide improves survival in patients with multiple myeloma.","volume":"108","author":"Attal","year":"2006","journal-title":"Blood"},{"issue":"11","key":"2019111807390352900_B16","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1200\/JCO.2008.18.8573","article-title":"Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure.","volume":"27","author":"Spencer","year":"2009","journal-title":"J Clin Oncol"},{"issue":"1","key":"2019111807390352900_B17","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood-2011-06-357038","article-title":"The role of maintenance thalidomide therapy in multiple myeloma: MRC myeloma IX results and meta-analysis.","volume":"119","author":"Morgan","year":"2012","journal-title":"Blood"},{"issue":"10","key":"2019111807390352900_B18","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1056\/NEJMoa053583","article-title":"Thalidomide and hematopoietic-cell transplantation for multiple myeloma.","volume":"354","author":"Barlogie","year":"2006","journal-title":"N Engl J Med"},{"issue":"8","key":"2019111807390352900_B19","doi-asserted-by":"crossref","first-page":"3115","DOI":"10.1182\/blood-2008-03-145235","article-title":"Thalidomide arm of total therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities.","volume":"112","author":"Barlogie","year":"2008","journal-title":"Blood"},{"issue":"7","key":"2019111807390352900_B20","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1200\/JCO.2009.25.6081","article-title":"Long-term follow-up of autotransplantation trials for multiple myeloma: update of protocols conducted by the Intergroupe Francophone du Myelome, Southwest Oncology Group, and University of Arkansas for Medical Sciences.","volume":"28","author":"Barlogie","year":"2010","journal-title":"J Clin Oncol"},{"issue":"6","key":"2019111807390352900_B21","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1182\/blood-2009-05-222539","article-title":"A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high dose melphalen followed by thalidomide maintenance in patients with multiple myelomas.","volume":"115","author":"Lokhorst","year":"2010","journal-title":"Blood"},{"issue":"21","key":"2019111807390352900_B22","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V116.21.39.39","article-title":"A randomized phase III trial of thalidomide and prednisone as maintenance therapy following autologous stem cell transplantation (ASCT) in patients with multiple myeloma (MM): the NCIC CTG MY10 Trial [abstract].","volume":"116","author":"Stewart","year":"2010","journal-title":"Blood"},{"key":"2019111807390352900_B23","article-title":"Improved progression-free and overall survival with thalidomide maintenance therapy after autologous stem cell transplantation in multiple myeloma: a meta-analysis of five randomized trials [abstract].","volume":"96","author":"Hahn-Ast","year":"2011","journal-title":"Hematologica"},{"issue":"11","key":"2019111807390352900_B24","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1038\/leu.2009.160","article-title":"The molecular characterization and clinical management of multiple myeloma in the post-genome era.","volume":"23","author":"Zhou","year":"2009","journal-title":"Leukemia"},{"issue":"9","key":"2019111807390352900_B25","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.3324\/haematol.2009.020586","article-title":"Thalidomide maintenance treatment increases progression-free but not overall survival in elderly patients with myeloma.","volume":"95","author":"Ludwig","year":"2010","journal-title":"Haematologica"},{"issue":"9513","key":"2019111807390352900_B26","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S0140-6736(06)68338-4","article-title":"Italian Multiple Myeloma Network, GIMEMA. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomized controlled trial.","volume":"367","author":"Palumbo","year":"2006","journal-title":"Lancet"},{"issue":"8","key":"2019111807390352900_B27","doi-asserted-by":"crossref","first-page":"3107","DOI":"10.1182\/blood-2008-04-149427","article-title":"Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized, controlled trial.","volume":"112","author":"Palumbo","year":"2008","journal-title":"Blood"},{"issue":"9594","key":"2019111807390352900_B28","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/S0140-6736(07)61537-2","article-title":"Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial.","volume":"370","author":"Facon","year":"2007","journal-title":"Lancet"},{"issue":"22","key":"2019111807390352900_B29","doi-asserted-by":"crossref","first-page":"3664","DOI":"10.1200\/JCO.2008.21.0948","article-title":"Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01\/01 Trial.","volume":"27","author":"Hulin","year":"2009","journal-title":"J Clin Oncol"},{"issue":"19","key":"2019111807390352900_B30","doi-asserted-by":"crossref","first-page":"3160","DOI":"10.1200\/JCO.2009.26.1610","article-title":"Phase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: the HOVON 49 Study.","volume":"28","author":"Wijermans","year":"2010","journal-title":"J Clin Oncol"},{"issue":"9","key":"2019111807390352900_B31","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1182\/blood-2009-08-237974","article-title":"Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma.","volume":"116","author":"Waage","year":"2010","journal-title":"Blood"},{"issue":"1","key":"2019111807390352900_B32","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/j.1600-0609.2010.01524.x","article-title":"Addition of thalidomide to oral melphalan\/prednisone in patients with multiple myeloma not eligible for transplantation: results of a randomized trial from the Turkish Myeloma Study Group.","volume":"86","author":"Beksac","year":"2011","journal-title":"Eur J Haematol"},{"issue":"10","key":"2019111807390352900_B33","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.3109\/10428194.2011.584006","article-title":"A randomized trial with melphalan and prednisone versus melphalan and prednisone plus thalidomide in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplant.","volume":"52","author":"Sacchi","year":"2011","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"2019111807390352900_B34","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1111\/j.1365-2141.2011.08689.x","article-title":"Lenalidomide downregulates the cell survival factor interferon regulatory factor-4, providing a potential mechanistic link for predicting response.","volume":"154","author":"Lopez-Girona","year":"2011","journal-title":"Br J Haematol"},{"issue":"18","key":"2019111807390352900_B35","doi-asserted-by":"crossref","first-page":"4771","DOI":"10.1182\/blood-2011-05-356063","article-title":"Cereblon expression is required for the antimyloma activity of lenalidomide and pomalidomide.","volume":"118","author":"Zhu","year":"2011","journal-title":"Blood"},{"key":"2019111807390352900_B36","doi-asserted-by":"crossref","first-page":"155","DOI":"10.2174\/156800910791054239","article-title":"Dexamethasone synergizes with lenalidomide to inhibit multiple myeloma tumor growth, but reduces lenalidomide-induced immunomodulation of T and NK cell function.","volume":"10","author":"Gandhi","year":"2010","journal-title":"Current Cancer Drug Targets"},{"issue":"5","key":"2019111807390352900_B37","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1200\/JCO.2009.22.7561","article-title":"Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation-maintenance in untreated multiple myeloma patients.","volume":"28","author":"Palumbo","year":"2010","journal-title":"J Clin Oncol"},{"issue":"s1","key":"2019111807390352900_B38","first-page":"IMW2011","article-title":"Phase III Intergroup study of lenalidomide versus placebo maintenance therapy following single autologous hematopoietic stem cell transplantation (AHSCT) for multiple myeloma (MM): CALGB ECOG BMT-CTN 100104 [abstract].","volume":"96","author":"McCarthy","year":"2011","journal-title":"Haematologica"},{"issue":"21","key":"2019111807390352900_B39","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V116.21.310.310","article-title":"Maintenance treatment with lenalidomide after transplantation for myeloma: final analysis of the IFM 2005-02 [abstract].","volume":"116","author":"Attal","year":"2010","journal-title":"Blood"},{"issue":"s1","key":"2019111807390352900_B40","first-page":"IMW 2011","article-title":"Maintenance treatment with lenalidomide after transplantation for myeloma: analysis of secondary malignancies within the IFM 2005-02 trial [abstract s23].","volume":"96","author":"Attal","year":"2011","journal-title":"Heamatologica"},{"issue":"28","key":"2019111807390352900_B41","doi-asserted-by":"crossref","first-page":"4459","DOI":"10.1200\/JCO.2007.12.3463","article-title":"Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA. Italian Multiple Myeloma Network.","volume":"25","author":"Palumbo","year":"2007","journal-title":"J Clin Oncol"},{"issue":"21","key":"2019111807390352900_B42","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V116.21.622.622","article-title":"A phase 3 study evaluating the efficacy and safety of lenalidomide combined with melphalan and prednisone in patients \u2265 65 years with newly diagnosed multiple myeloma (NDMM): continuous use of lenalidomide vs fixed-duration regimens [abstract].","volume":"116","author":"Palumbo","year":"2010","journal-title":"Blood"},{"issue":"21","key":"2019111807390352900_B43","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V118.21.475.475","article-title":"A phase 3 study evaluating the efficacy and safety of lenalidomide combined with melphalan and prednisone followed by continuous lenalidomide maintenance (MPR-R) in patients \u2265 65 years with newly diagnosed multiple myeloma (NDMM): updated results for patients aged 65-75 years enrolled in MM-015 [abstract].","volume":"118","author":"Palumbo","year":"2011","journal-title":"Blood"},{"issue":"21","key":"2019111807390352900_B44","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V118.21.477.477","article-title":"Maintenance therapy with bortezomib plus thalidomide (VT) or bortezomib plus prednisone (VP) in elderly myeloma patients included in the GEM2005MAS65 Spanish randomized trial [abstract].","volume":"118","author":"Mateos","year":"2011","journal-title":"Blood"},{"issue":"34","key":"2019111807390352900_B45","doi-asserted-by":"crossref","first-page":"5101","DOI":"10.1200\/JCO.2010.29.8216","article-title":"Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial.","volume":"28","author":"Palumbo","year":"2010","journal-title":"J Clin Oncol"},{"issue":"21","key":"2019111807390352900_B46","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V116.21.40.40","article-title":"HOVON-65\/GMMG-HD4 randomized phase III trial comparing bortezomib, doxorubicin, dexamethasone (PAD) vs VAD followed by high-dose melphalan (HDM) and maintenance with bortezomib or thalidomide in patients with newly diagnosed multiple myeloma (MM) [abstract].","volume":"116","author":"Sonneveld","year":"2010","journal-title":"Blood"},{"issue":"21","key":"2019111807390352900_B47","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V116.21.2396.2396","article-title":"Influence of renal function on outcome of VAD or bortezomib, doxorubicin, dexamethasone (PAD) induction treatment followed by high-dose melphalan (HDM): a subgroup analysis from the HOVON-65\/GMMG-HD4 randomized phase III trial for newly diagnosed multiple myeloma [abstract].","volume":"116","author":"Scheid","year":"2010","journal-title":"Blood"},{"issue":"21","key":"2019111807390352900_B48","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V116.21.305.305","article-title":"Bortezomib-based induction therapy followed by autologous stem cell transplantation and maintenance therapy with bortezomib improves outcome in myeloma patients with gain 1q21 and t(4; 14): a subgroup analysis of the HOVON-65\/GMMG-HD4 trial [abstract].","volume":"116","author":"Goldschmidt","year":"2010","journal-title":"Blood"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/119\/13\/3003\/1348573\/zh801312003003.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/119\/13\/3003\/1348573\/zh801312003003.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,18]],"date-time":"2019-11-18T12:48:54Z","timestamp":1574081334000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/119\/13\/3003\/29610\/IMWG-consensus-on-maintenance-therapy-in-multiple"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,3,29]]},"references-count":48,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2012,3,29]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2011-11-374249","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,3,29]]}}}